Transthyretin Stabilizers Market Outlook:
Transthyretin Stabilizers Market size was over USD 15.23 billion in 2025 and is projected to reach USD 35.73 billion by 2035, witnessing around 8.9% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of transthyretin stabilizers is evaluated at USD 16.45 billion.
The market is witnessing a robust surge, driven primarily by the escalating prevalence of transthyretin amyloidosis (ATTR). ATTR, a rare and debilitating disease, is characterized by the abnormal accumulation of transthyretin protein, leading to organ dysfunction and a myriad of clinical manifestations.
As the incidence of ATTR rises globally, the demand for effective therapeutic interventions, including transthyretin stabilizers, is experiencing unprecedented growth. According to a recent epidemiological study, the global prevalence of ATTR has exhibited a significant increase over the past decade. In 2010, the estimated prevalence of ATTR was 10 cases per 100,000 populations, and by 2020, this figure had surged to 25 cases per 100,000 populations. This compelling statistic underscores the urgent need for therapeutic interventions, driving significant growth in the market.
Transthyretin stabilizers are drugs designed to stabilize the transthyretin protein, preventing its misfolding and aggregation into amyloid fibrils. By stabilizing the protein, these drugs aim to slow down or halt the progression of ATTR and alleviate associated symptoms. Several transthyretin stabilizers were under development by various pharmaceutical companies. Among them, tafamidis was one of the first drugs to receive regulatory approval for the treatment of transthyretin familial amyloid polyneuropathy (TTR-FAP) in some regions.
